Department of Surgical Sciences and Integrated Diagnostic (DISC), School of Medicine, University of Genoa, Genoa, Italy.
Breast Surgery Clinic, San Martino Policlinic Hospital, Genoa, Italy.
Anticancer Res. 2020 Jun;40(6):3543-3550. doi: 10.21873/anticanres.14343.
BACKGROUND/AIM: A retrospective study was performed in 246 breast cancer patients to define whether tumor-to-nipple distance (TND) assessment by breast MRI may select patients eligible to nipple-sparing mastectomy (NSM) as compared to permanent section assessment of retroareolar margin.
Pre- and post-operative parameters including imaging data, histology of the primary tumor, biologic prognostic factors, and adjuvant regimens were retrieved; patients with close/positive retroareolar margins underwent nipple or NAC excision. The primary endpoint was loco-regional recurrence (LRR).
Patients with TND ≤2 cm had a significantly higher rate of invasive ductal carcinoma (p<0.003) and excision margins less than 2 mm (p<0.000). Eleven retroareolar specimens were positive at definitive pathology; final re-excision specimen examination showed residual disease in seven patients (63.6%). At a median follow-up of 31 to 33 months, no NAC recurrence did occur; disease-free survival was more than 96%, and LRR was homogeneously distributed among TND subgroups.
Therapeutic NSM is a safe procedure independently of TND assessed at preoperative breast MRI. Permanent section assessment of retroareolar tissue is more accurate and cost-effective than frozen section. Furthermore, delayed nipple and/or NAC excision did not impair local disease control.
背景/目的:本回顾性研究纳入了 246 例乳腺癌患者,旨在评估乳腺 MRI 测量的肿瘤至乳头距离(TND)是否可选择适合保乳乳头乳晕复合体保留术(NSM)的患者,与乳晕后缘的永久性切片评估相比。
回顾性分析了术前和术后的参数,包括影像学数据、原发性肿瘤的组织学、生物学预后因素和辅助治疗方案;对于切缘接近/阳性的患者行乳头或乳头乳晕复合体切除术。主要终点是局部区域复发(LRR)。
TND≤2cm 的患者浸润性导管癌的发生率显著更高(p<0.003),切缘小于 2mm 的比例更高(p<0.000)。11 例乳晕后缘标本在最终病理检查中呈阳性,7 例患者(63.6%)的再次切除标本中仍有肿瘤残留。在 31 至 33 个月的中位随访期间,未发生乳头乳晕复合体复发;无病生存率>96%,且 TND 亚组之间 LRR 分布均匀。
术前乳腺 MRI 评估的 TND 并不影响保乳手术的安全性。乳晕后缘组织的永久性切片评估比冷冻切片更准确且更具成本效益。此外,延迟切除乳头和/或乳头乳晕复合体并未影响局部疾病控制。